ABSTRACT
Background: Chronic cough (cough lasting for ≥8â weeks) can lead to significant impairment in quality of life (QoL). Using patient-reported outcomes, this cohort study assessed the perceived impact of chronic cough on QoL and everyday life in patients from outpatient hospital clinics with refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods: This was a multicentre, non-interventional survey study. Cough severity was assessed on a 0-100â mm Visual Analogue Scale (VAS). Frequency, intensity and disruptiveness of cough were assessed using an adaptation of the Cough Severity Diary. The impact of cough on QoL was assessed using the Leicester Cough Questionnaire (LCQ). The physical impact of cough and associated impact on everyday life activities were explored using purpose-designed questions. Results: 191 patients responded to the survey; 121 (63.4%) had RCC and 149 were women (78.0%). Mean score on the cough severity VAS was 62.9â mm. Mean LCQ total score of 11.9 indicated reduced QoL. Cough impaired patients' everyday life, including the inability to speak fluently (58.0% of patients) and feeling tired/drained (46.6%). Women perceived poorer chronic cough-related QoL than men, as reflected by lower LCQ scores, and greater impairment of physical health, including cough-related stress urinary incontinence, and psychological health. Conclusions: Patients with RCC/UCC experience a significant burden in their everyday life, including impaired QoL, and perceive a negative impact on physical and psychological health and everyday activities, affecting work, relationships and leisure activities. The impact appears to be greater in women than men for several of the aspects studied.
ABSTRACT
No disponible
Subject(s)
Humans , Male , Infant , Fractures, Closed/diagnostic imaging , Tibial Fractures/diagnostic imagingABSTRACT
No disponible
Subject(s)
Humans , Female , Child , Erythema Chronicum Migrans/diagnosis , Erythema Chronicum Migrans/drug therapy , Borrelia Infections/complications , Borrelia Infections/drug therapy , Borrelia burgdorferi , Borrelia burgdorferi/isolation & purification , Medical History Taking/methods , Medical History Taking/standards , Immunoglobulin G/administration & dosage , Immunoglobulin G/analysis , Seroconversion , Lyme Disease/drug therapy , Lyme Disease/epidemiologySubject(s)
Fractures, Closed/diagnostic imaging , Tibial Fractures/diagnostic imaging , Humans , Infant , MaleABSTRACT
AIMS: To establish the optimal dose of Phleum pratense subcutaneous immunotherapy (SCIT) in patients with allergic rhinoconjunctivitis with/without asthma. MATERIALS & METHODS: One hundred and fifty-one patients were randomized to receive SCIT 0.25, 0.5, 1.0, 2.0 or 4.0 skin-prick test units (SPT) or placebo. The primary end point was the variation in the concentration of Phleum pratense extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV). RESULTS: After 17 weeks, a dose-dependent trend was apparent in the concentration of P. pratense extract needed to produce a positive nasal provocation response. Systemic adverse reactions occurred with 3.2% of administered doses. Grade III (n = 2) and IV (n = 2) events were observed only at the two highest doses. CONCLUSION: P. pratense depot SCIT showed signs of clinical and immunological efficacy by dose-dependently decreasing the allergen sensitization rate. Risk-benefit favored doses below 1.0 SPT units for confirmatory trials.
Subject(s)
Allergens/administration & dosage , Antigens, Plant/administration & dosage , Asthma/therapy , Conjunctivitis, Allergic/therapy , Desensitization, Immunologic , Phleum/immunology , Rhinitis, Allergic, Seasonal/therapy , Rhinitis, Allergic/therapy , Adult , Allergens/adverse effects , Antigens, Plant/adverse effects , Asthma/complications , Asthma/immunology , Conjunctivitis, Allergic/complications , Conjunctivitis, Allergic/immunology , Dose-Response Relationship, Immunologic , Female , Follow-Up Studies , Humans , Injections, Subcutaneous , Male , Middle Aged , Nasal Provocation Tests , Pollen/immunology , Portugal , Rhinitis, Allergic/complications , Rhinitis, Allergic/immunology , Rhinitis, Allergic, Seasonal/complications , Rhinitis, Allergic, Seasonal/immunology , Risk Assessment , Spain , Young AdultSubject(s)
Erythema Chronicum Migrans , Child , Erythema Chronicum Migrans/diagnosis , Female , HumansABSTRACT
AIM: A double-blind placebo-controlled study was conducted according to EMA guidelines, to evaluate safety, tolerability and short-term treatment effects of three up-dosing regimens of Phleum pratense subcutaneous immunotherapy. MATERIALS & METHODS: Forty-two patients were randomized to groups: A (6 weekly doses), B (8 weekly doses) or C (eight doses, two clustered increasing doses over 3 weeks). RESULTS: The most frequent adverse events were local reactions. No serious adverse events were found. Higher number and more severe systemic reactions were reported in group C. A decrease in cutaneous responses and an increase of specific antibodies was shown in all active groups even at very short-term. CONCLUSION: Phleum pratense subcutaneous immunotherapy in depot presentation exhibited good safety and tolerability. Group A seemed to show the best profile.
Subject(s)
Desensitization, Immunologic/methods , Rhinitis, Allergic, Seasonal/therapy , Vaccines/administration & dosage , Adult , Allergens/immunology , Antigens, Plant/immunology , Clinical Protocols , Double-Blind Method , Female , Humans , Injections, Subcutaneous , Male , Middle Aged , Phleum/immunology , Placebo Effect , Plant Extracts/immunology , Pollen/immunology , Practice Guidelines as Topic , Rhinitis, Allergic, Seasonal/immunology , Spain , Treatment Outcome , Vaccines/immunology , Young AdultABSTRACT
We studied by real-time PCR cyclin D1 and thymidylate synthase (TS) mRNA in plasma as possible markers of clinical outcome in breast cancer. We observed poor outcome in patients with presence of cyclin D1 mRNA in good-prognosis groups, such as negative vascular invasion. Presence of both markers was associated with non-response to treatment after relapse. In patients treated with tamoxifen, a trend to significant relation between poor outcome and cyclin D1 mRNA was found. Cyclin D1 mRNA in plasma could identify patients with poor overall survival in good-prognosis groups and patients non-responsive to tamoxifen.
Subject(s)
Breast Neoplasms/blood , Cyclin D1/analysis , RNA, Messenger/blood , Thymidylate Synthase/genetics , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Cyclin D1/blood , Disease-Free Survival , Female , Humans , Prognosis , Prospective Studies , Survival Analysis , Tamoxifen/therapeutic use , Thymidylate Synthase/blood , Treatment OutcomeABSTRACT
Presentamos a una paciente de 26 años con obesidad mórbida, a la que realizamos colecistectomía profiláctica, biopsia hepática, gastroplastia vertical anillada con banda de polipropileno (7 cm de largo, adosada 1,5 cm, quedando una neoboca de 5,5 cm y 1,5 cm de ancho), sección del estómago vertical con GIA y sutura de refuerzo. Durante el postoperatorio presentó regurgitación, dificultad para la alimentación y vómitos alimentarios. Reingresó por un cuadro neurológico agudo: encefalopatía, oftalmoplejía, confusión mental y estupor. Se encuadra dentro del síndrome de Wernicke-Korsakoff, como consecuencia de déficit alimentario, disminución de tiamina y adelgazamiento rápido. Se instauró tratamiento con nutrición parenteral total y altas dosis de tiamina, con lo que la paciente se recuperó al poco tiempo de su reingreso en el hospital, siendo seguida en el Servicio de Neurología de este centro (AU)